Editas Medicine (EDIT) Tops Q2 EPS by 3c

Editas Medicine (NASDAQ: EDIT) reported Q2 EPS of ($0.78), $0.03 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $6.36 million versus the consensus estimate of $4.29 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Copart to buy ACV for $1.9 billion in cash deal
• IBEX Limited (IBEX) Tops Q4 EPS by 6c; offers guidance